Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.
about
Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic optionsPertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerHER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast CancerCost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-AnalysisPertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations.Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial.The expanding role of pertuzumab in the treatment of HER2-positive breast cancerHER story: the next chapter in HER-2-directed therapy for advanced breast cancer.Health-related Quality of Life in Metastatic and Adjuvant Breast Cancer Patients.Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trialBreast cancer, version 3.2013: featured updates to the NCCN guidelines.Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer.Pertuzumab for the treatment of breast cancer.Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy.A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity - CLEOPATRA and PENELOPE.Pertuzumab for the treatment of breast cancer: a safety review.The use of patient-reported outcomes in advanced breast cancer clinical trials: a review of the published literature.Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial.Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment.Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology.ESMO-Magnitude of Clinical Benefit Scale version 1.1.Real-World Data on Health-Related Quality of Life Assessment in Patients With Breast Cancer Receiving Subcutaneous Trastuzumab.Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.Metastatic and triple-negative breast cancer: challenges and treatment options
P2860
Q26777681-4830F050-31C5-4084-BBAC-6F384F9B9B4DQ27853134-7DEE0C60-3411-410B-BDB7-D7A475A4AA62Q28237833-171A06CE-BEF4-4A1E-BB8C-B5C52F090941Q28267134-42579425-F921-40A6-B94A-5116177E16F2Q28547354-59DCA9BD-BCF7-4667-AF46-4CABA401825DQ33680109-A806922A-C6DE-4E42-8BFE-C4E157295DDCQ35641643-6E04AE6E-D3D4-469B-B75C-BB599AEDA5F6Q35653163-2BEBEF5A-4596-4B7D-97EB-A2F8495634C2Q37301435-4C6DBA8B-F692-432F-B89D-56037BFC13EFQ37341647-82F425AA-7C6F-40DC-8AB8-D24430A4C33BQ37620096-3C5F94DD-A808-48D8-AECE-A9DD3A9F3BCDQ37709567-632712E0-615D-4054-8B4F-EFBB4CCD7770Q38132047-F85C4893-1AAA-4CB9-8DBA-DDBD1E8AF47CQ38219674-29302368-DC67-420C-993B-735D9AA6C681Q38286163-6A3B545A-26D9-48A9-A093-6E9C462D8DCBQ38573858-26024853-5645-4823-BE8C-18771860FD0CQ38644521-6A4A43D5-E021-4B24-B5B2-89C26AFFAF9BQ38776876-93D78487-201A-4A81-A306-74FBA8767754Q38872926-D592D668-19BE-45DB-A6D8-1BD6593BA2C1Q42236299-649AD254-E26D-4999-BDDE-77231B229D04Q47103332-96FFEC0F-69A9-44E7-A046-EC0BAE224EE0Q48037262-8FBF6038-5440-4996-8104-CBE4007ED02EQ49842557-A4A154B9-535C-4663-AC2E-37A035B4271EQ53839396-107E1F9E-5AC6-4B0D-947F-225124BDFCBCQ55365709-8B108C07-8A06-4F8B-8154-3CDDEAA72EF6Q57105258-A0518BE8-C835-49BF-980B-8A55FB749D5A
P2860
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Health-related quality-of-life ...... l in metastatic breast cancer.
@en
Health-related quality-of-life ...... l in metastatic breast cancer.
@nl
type
label
Health-related quality-of-life ...... l in metastatic breast cancer.
@en
Health-related quality-of-life ...... l in metastatic breast cancer.
@nl
prefLabel
Health-related quality-of-life ...... l in metastatic breast cancer.
@en
Health-related quality-of-life ...... l in metastatic breast cancer.
@nl
P2093
P2860
P50
P356
P1433
P1476
Health-related quality-of-life ...... l in metastatic breast cancer.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDT274
P577
2013-07-17T00:00:00Z